The BCM3 facility features a versatile dual-function design capable of handling both antibody intermediates and conjugated drug substances. With batch capacities scaling from 200 liters to 2,000 liters, the site is built to manage commercial-grade manufacturing while maintaining rigorous quality control. The project reached completion in two and a half years, a timeline the company attributes to applying established construction expertise from its Wuxi site to local conditions in Singapore.

Integration between the new Singapore hub and existing Wuxi production lines remains a priority for the firm. By coordinating BCM3 with the established BCM1 and BCM2 lines, WuXi XDC aims to provide a more resilient manufacturing foundation for international partners. The company has already set its next objective, with a drug product filling line, DP4, slated for GMP release by the end of August 2026. This expansion reflects a broader strategy to pair global service reach with localized responsiveness, ensuring that clients can pivot between production sites as market demands fluctuate.